Unicycive Quick Ratio from 2010 to 2024

UNCY Stock  USD 0.68  0  0.29%   
Unicycive Therapeutics Quick Ratio yearly trend continues to be fairly stable with very little volatility. Quick Ratio is likely to outpace its year average in 2024. Quick Ratio is a measure of a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as (current assets - inventories) divided by current liabilities. View All Fundamentals
 
Quick Ratio  
First Reported
2010-12-31
Previous Quarter
0.76417246
Current Value
1.39
Quarterly Volatility
2.2370019
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Unicycive Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Unicycive Therapeutics' main balance sheet or income statement drivers, such as Interest Expense of 77.9 K, Net Interest Income of 429.4 K or Depreciation And Amortization of 386.4 K, as well as many indicators such as Price To Sales Ratio of 16.04, Dividend Yield of 0.0 or Days Sales Outstanding of 0.0. Unicycive financial statements analysis is a perfect complement when working with Unicycive Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Unicycive Therapeutics Correlation against competitors.
For more information on how to buy Unicycive Stock please use our How to Invest in Unicycive Therapeutics guide.

Latest Unicycive Therapeutics' Quick Ratio Growth Pattern

Below is the plot of the Quick Ratio of Unicycive Therapeutics over the last few years. It is a measure of a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as (current assets - inventories) divided by current liabilities. Unicycive Therapeutics' Quick Ratio historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Unicycive Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Quick Ratio10 Years Trend
Slightly volatile
   Quick Ratio   
       Timeline  

Unicycive Quick Ratio Regression Statistics

Arithmetic Mean0.80
Geometric Mean0.08
Coefficient Of Variation279.42
Mean Deviation1.14
Median0.02
Standard Deviation2.24
Sample Variance5.00
Range8.7253
R-Value0.38
Mean Square Error4.62
R-Squared0.14
Significance0.16
Slope0.19
Total Sum of Squares70.06

Unicycive Quick Ratio History

2024 1.39
2023 0.76
2022 0.81
2021 8.75
2020 0.071
2019 0.021

About Unicycive Therapeutics Financial Statements

Unicycive Therapeutics investors use historical fundamental indicators, such as Unicycive Therapeutics' Quick Ratio, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Unicycive Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Quick Ratio 0.76  1.39 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Unicycive Stock Analysis

When running Unicycive Therapeutics' price analysis, check to measure Unicycive Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Unicycive Therapeutics is operating at the current time. Most of Unicycive Therapeutics' value examination focuses on studying past and present price action to predict the probability of Unicycive Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Unicycive Therapeutics' price. Additionally, you may evaluate how the addition of Unicycive Therapeutics to your portfolios can decrease your overall portfolio volatility.